文献速递脑血管病

舌下含服依达拉奉右莰醇治疗急性缺血性卒中:TASTE-SL随机临床试验

Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2024-02-19

这项双盲、安慰剂对照、多中心3期随机临床试验在中国33个中心纳入914例急性缺血性卒中患者,评估舌下含服依达拉奉右莰醇(依达拉奉30 mg、右莰醇6 mg,每日两次,共14天)对比安慰剂对90天功能结局的影响。结果显示,治疗组90天mRS评分≤1分的比例显著高于安慰剂组(64.4% vs 54.7%;风险差9.70%;OR 1.50,P=0.003),两组不良事件发生率相似。

要点

  • 舌下含服依达拉奉右莰醇(30 mg/6 mg,每日两次,14天)较安慰剂提高90天良好功能结局比例。
  • 主要疗效:mRS≤1分比例64.4% vs 54.7%,风险差9.70%(95%CI 3.37%-16.03%),OR 1.50(95%CI 1.15-1.95,P=0.003)。
  • 安全性:不良事件发生率两组相似(89.8% vs 90.1%)。

核心结论

  • 在急性缺血性卒中48小时内的患者中,舌下含服依达拉奉右莰醇较安慰剂可提高90天良好功能结局的比例。

研究设计与样本

  • 双盲、安慰剂对照、多中心、平行组3期随机临床试验,于2021年6月28日至2022年8月10日在中国33个中心开展,随访90天。
  • 共914例患者按1:1随机分配至依达拉奉右莰醇组(450例)或安慰剂组(464例),年龄18至80岁,NIHSS评分6至20分,上下肢总运动缺损评分≥2分,卒中前mRS≤1分。

主要发现

  • 90天mRS≤1分比例:依达拉奉右莰醇组290例(64.4%) vs 安慰剂组254例(54.7%);风险差9.70%(95%CI 3.37%-16.03%);OR 1.50(95%CI 1.15-1.95,P=0.003)。
  • 不良事件发生率:依达拉奉右莰醇组89.8%(405/450) vs 安慰剂组90.1%(418/464),两组相似。

关键数值与推荐

  • 主要疗效终点为随机化后90天mRS评分≤1分的患者比例。
  • 干预方案:舌下含服依达拉奉右莰醇(依达拉奉30 mg、右莰醇6 mg)或安慰剂(依达拉奉0 mg、右莰醇60 μg),每日两次,共14天。

临床怎么用

  • 对于急性缺血性卒中48小时内、符合纳入标准的患者,舌下含服依达拉奉右莰醇(30 mg/6 mg,每日两次,14天)可提高90天良好功能结局比例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sublingual edaravone dexborneol, which can rapidly diffuse and be absorbed through the oral mucosa after sublingual exposure, is a multitarget brain cytoprotection composed of antioxidant and anti-inflammatory ingredients edaravone and dexborneol. OBJECTIVE: To investigate the efficacy and safety of sublingual edaravone dexborneol on 90-day functional outcome in patients with acute ischemic stroke (AIS). DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled, multicenter, parallel-group, phase 3 randomized clinical trial conducted from June 28, 2021, to August 10, 2022, with 90-day follow-up. Participants were recruited from 33 centers in China. Patients randomly assigned to treatment groups were aged 18 to 80 years and had a National Institutes of Health Stroke Scale score between 6 and 20, a total motor deficit score of the upper and lower limbs of 2 or greater, a clinically diagnosed AIS symptom within 48 hours, and a modified Rankin Scale (mRS) score of 1 or less before stroke. Patients who did not meet the eligibility criteria or declined to participate were excluded. INTERVENTION: Patients were assigned, in a 1:1 ratio, to receive sublingual edaravone dexborneol (edaravone, 30 mg; dexborneol, 6 mg) or placebo (edaravone, 0 mg; dexborneol, 60 μg) twice daily for 14 days and were followed up until 90 days. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the proportion of patients with mRS score of 1 or less on day 90 after randomization. RESULTS: Of 956 patients, 42 were excluded. A total of 914 patients (median [IQR] age, 64.0 [56.0-70.0] years; 608 male [66.5%]) were randomly allocated to the edaravone dexborneol group (450 [49.2%]) or placebo group (464 [50.8%]). The edaravone dexborneol group showed a significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization compared with the placebo group (290 [64.4%] vs 254 [54.7%]; risk difference, 9.70%; 95% CI, 3.37%-16.03%; odds ratio, 1.50; 95% CI, 1.15-1.95, P = .003). The rate of adverse events was similar between the 2 groups (89.8% [405 of 450] vs 90.1% [418 of 464]). CONCLUSION AND RELEVANCE: Among patients with AIS within 48 hours, sublingual edaravone dexborneol could improve the proportion of those achieving a favorable functional outcome at 90 days compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04950920.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Fu Y, Wang A, Tang R, et al. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38372981. doi:10.1001/jamaneurol.2023.5716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。